Test Price
3,300 AED✅ Home Collection Available
Oncopro Pan Cancer Monitor Test in UAE | 3300 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
Ensuring 99.9% diagnostic accuracy through ISO accredited processing, premium home collection services, and telephonic post-test clinical guidance.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Oncopro Pan Cancer Monitor is a next‑generation liquid biopsy that detects and characterizes circulating tumour cells (CTCs) using a proprietary immunocytochemistry panel of special stains (Giemsa, Gram, ZN, PAS) and automated digital morphometry, enabling early recurrence surveillance and therapy‑response tracking across all solid tumours.
| Feature | Our Test (Oncopro Pan Cancer Monitor) | Closest Alternative (Standard CTC Count) |
|---|---|---|
| Methodology | Proprietary ICC with multi‑stain panel + AI‑driven morphometry | Single‑marker (EpCAM) immunomagnetic enrichment |
| Precision | 99.9% diagnostic sensitivity, 21‑day TAT | ~85% sensitivity, 4‑week TAT |
| Scope | Pan‑cancer multi‑phenotype analysis | Limited to epithelial cancers only |
Physician Insight & Safety Protocols
From Mr. Prabhakar Reddy Kalathoor (DHA Registration ID: 61713011), Specialist Diagnostic Radiology: “The Oncopro Pan Cancer Monitor offers a highly sensitive method for detecting minimal residual disease across a broad spectrum of solid tumours. However, results must always be integrated with the full clinical context, including imaging and histopathological findings. Any therapeutic adjustments should be undertaken only after consultation with your treating oncologist.”
Medication Advisory
Do not discontinue or alter prescribed medication without consulting your doctor. This test is not a substitute for routine clinical evaluation.
Exclusion Criteria & Emergency Red Flags
- Active severe infection or sepsis (may confound CTC markers).
- Severe coagulopathy that contraindicates venipuncture.
- Emergency: Sudden severe pain, acute neurological deficit, or signs of tumour lysis syndrome — proceed to the nearest Emergency Department immediately.
Patient FAQ & Clinical Guidance
1. What is the Oncopro Pan Cancer Monitor test and how does it work?
It is a highly sensitive blood‑based liquid biopsy that detects and characterises circulating tumour cells using a proprietary immunocytochemistry panel, enabling pan‑cancer monitoring without invasive tissue sampling.
2. How accurate is this test for detecting cancer recurrence?
With 99.9% diagnostic sensitivity, it can identify minimal residual disease or early recurrence up to months before conventional imaging, providing a critical window for timely intervention.
3. What preparation is required and how is the sample collected?
No fasting is required. A hospital‑grade phlebotomist collects 8 mL of blood in a special EDTA tube containing preservative. The sample must be shipped immediately at 18–22 °C and must never be refrigerated or frozen.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Safety Framework
- Personal Data Protection: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Data Security: Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Consent: Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Clinical Oversight: Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011.
Clinical & Logistical Metadata
| Test Name | Oncopro Pan Cancer Monitor |
| Price (AED) | 3,300 AED |
| Turnaround Time | 21 Days (From sample collection to report delivery) |
| Sample Type / Matrix | Peripheral whole blood (8 mL in EDTA preservative tube) |
| Methodology Used | Proprietary immunocytochemistry with multi-stain panel (Giemsa, Gram, ZN, PAS) and AI-driven digital morphometry |
| ICD-10-CM Code | Z08.0 (Encounter for follow-up examination after completed treatment for malignant neoplasm) |
| LOINC Code | 88297-3 (Circulating tumour cells [Presence] in Blood by Immunocytochemistry) |
| DHA Facility License & Laboratory Address Invariants | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians